S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   271.35 (+2.32%)
AAPL   451.84 (+3.28%)
MSFT   208.65 (+2.59%)
FB   259.42 (+1.28%)
GOOGL   1,507.25 (+1.80%)
AMZN   3,160.57 (+2.59%)
NVDA   457.50 (+5.41%)
CGC   17.24 (+1.71%)
BABA   255.02 (+2.66%)
TSLA   1,557.10 (+13.29%)
GE   6.70 (-0.45%)
MU   48.40 (+1.34%)
AMD   82.69 (+7.56%)
T   30.17 (-0.10%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.71 (+0.90%)
NFLX   474.60 (+1.64%)
DIS   131.52 (+0.79%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:CVETCovetrus Stock Price, Forecast & News

$22.71
-0.38 (-1.65 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$21.92
Now: $22.71
$25.00
50-Day Range
$17.38
MA: $20.18
$23.67
52-Week Range
$4.05
Now: $22.71
$24.99
Volume71,641 shs
Average Volume1.60 million shs
Market Capitalization$2.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
Current SymbolNASDAQ:CVET
CUSIPN/A
CIKN/A
Phone888-280-2221

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.98 billion
Cash Flow$10.61 per share
Book Value$11.20 per share

Profitability

Net Income$-1,019,000,000.00

Miscellaneous

Employees5,500
Market Cap$2.54 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$22.71
-0.38 (-1.65 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVET News and Ratings via Email

Sign-up to receive the latest news and ratings for CVET and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Covetrus (NASDAQ:CVET) Frequently Asked Questions

How has Covetrus' stock price been impacted by COVID-19 (Coronavirus)?

Covetrus' stock was trading at $9.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CVET stock has increased by 151.2% and is now trading at $22.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Covetrus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Covetrus
.

When is Covetrus' next earnings date?

Covetrus is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Covetrus
.

How were Covetrus' earnings last quarter?

Covetrus Inc (NASDAQ:CVET) announced its quarterly earnings results on Tuesday, August, 11th. The company reported $0.27 EPS for the quarter, topping the Zacks' consensus estimate of $0.08 by $0.19. The company earned $1.03 billion during the quarter, compared to analysts' expectations of $892.90 million. Covetrus had a positive return on equity of 4.84% and a negative net margin of 24.05%. Covetrus's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.09) earnings per share.
View Covetrus' earnings history
.

What price target have analysts set for CVET?

4 equities research analysts have issued 1-year target prices for Covetrus' shares. Their forecasts range from $11.00 to $26.00. On average, they expect Covetrus' share price to reach $18.50 in the next twelve months. This suggests that the stock has a possible downside of 18.5%.
View analysts' price targets for Covetrus
.

Has Covetrus been receiving favorable news coverage?

News coverage about CVET stock has been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Covetrus earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Covetrus
.

Are investors shorting Covetrus?

Covetrus saw a increase in short interest in January. As of January 31st, there was short interest totaling 17,740,000 shares, an increase of 18.5% from the January 15th total of 14,970,000 shares. Based on an average daily trading volume, of 1,610,000 shares, the days-to-cover ratio is currently 11.0 days. Approximately 18.2% of the company's stock are sold short.
View Covetrus' Short Interest
.

Who are some of Covetrus' key competitors?

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include NVIDIA (NVDA), Pfizer (PFE), Taiwan Semiconductor Mfg. (TSM), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Chegg (CHGG), Evolent Health (EVH), General Mills (GIS), IDEXX Laboratories (IDXX) and Livongo Health (LVGO).

Who are Covetrus' key executives?

Covetrus' management team includes the following people:
  • Benjamin J. Shaw, President, Chief Executive Officer & Director
  • Christine Tomlinson Komola, Chief Financial Officer & Executive Vice President
  • Matthew Leonard, Executive VP & President-North America
  • Jim Young, Chief Human Resources Officer & Senior VP
  • Erin Powers Brennan, Secretary, Senior Vice President & General Counsel

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional investors include BNP PARIBAS ASSET MANAGEMENT Holding S.A. (1.30%), Bank of New York Mellon Corp (1.03%), Palisade Capital Management LLC NJ (0.82%), Principal Financial Group Inc. (0.66%), New York State Common Retirement Fund (0.21%) and Swiss National Bank (0.20%). Company insiders that own Covetrus stock include Benjamin Shaw, Betsy S Atkins, David Christopher Dollar, Edward Mcnamara, Erin Powers Brennan and Timothy Ludlow.
View institutional ownership trends for Covetrus
.

Which major investors are selling Covetrus stock?

CVET stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., Prudential Financial Inc., Russell Investments Group Ltd., UBS Group AG, State Board of Administration of Florida Retirement System, Barclays PLC, Principal Financial Group Inc., and New York State Common Retirement Fund. Company insiders that have sold Covetrus company stock in the last year include Edward Mcnamara, and Timothy Ludlow.
View insider buying and selling activity for Covetrus
.

Which major investors are buying Covetrus stock?

CVET stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, SG Americas Securities LLC, Tuttle Tactical Management, WINTON GROUP Ltd, Swiss National Bank, Teza Capital Management LLC, Centric Wealth Management, and New York State Teachers Retirement System. Company insiders that have bought Covetrus stock in the last two years include Benjamin Shaw, and Erin Powers Brennan.
View insider buying and selling activity for Covetrus
.

How do I buy shares of Covetrus?

Shares of CVET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $22.71.

How big of a company is Covetrus?

Covetrus has a market capitalization of $2.54 billion and generates $3.98 billion in revenue each year. The company earns $-1,019,000,000.00 in net income (profit) each year or $0.79 on an earnings per share basis. Covetrus employs 5,500 workers across the globe.

What is Covetrus' official website?

The official website for Covetrus is www.henryscheinvet.com.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The company can be reached via phone at 888-280-2221 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.